{"analyses":[{"ciLowerLimit":"0.535","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.341","estimateComment":"HR obtained by unadjusted Cox's proportional hazard regression model stratified by age,international staging system(ISS),prior lines of therapy. HR\\<1 was deemed to indicate better PFS in Ixazomib+Dexamethasone arm over Pomalidomide+Dexamethasone arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.477","paramType":"Hazard Ratio (HR)","paramValue":"0.847","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.745","upperLimit":"8.542","value":"4.8"},{"groupId":"OG001","lowerLimit":"3.943","upperLimit":"11.138","value":"7.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"PFS: Time from randomization to first occurrence of confirmed progressive disease (PD) as assessed by investigator by International Myeloma Working Group(IMWG) response criteria/death from any cause, whichever occurs first. PD requires following: Increase of \\>=25 % from nadir in: Serum M component (increase must be \\>=0.5 gram per deciliter \\[g/dl\\]); Urine M-component (increase must be \\>=200 milligram \\[mg\\]/24-hour); In participants without measurable serum and urine M-protein levels difference between involved and uninvolved free light chain (FLC) increase of \\>10 mg/dl; In participants without measurable serum and urine M protein levels and without measurable disease by FLC level: bone marrow plasma cell percentage must be \\>=10%; Development of new/increase in size of existing bone lesions/soft tissue plasmacytomas; development of hypercalcemia (\\>11.5mg/dL corrected serum calcium) attributed solely to plasma cell proliferative disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG000","title":"Pomalidomide 4 mg + Dexamethasone 40 mg"},{"description":"Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG001","title":"Ixazomib 4 mg + Dexamethasone 20 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants who were randomized. Participants without documentation of PD were censored at the date of last response assessment that is stable disease (SD) or better.","reportingStatus":"POSTED","timeFrame":"From date of randomization until first occurrence of confirmed disease progression or death due to any cause, whichever occurs first (Up to approximately 3 years)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}